These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
981 related articles for article (PubMed ID: 35533497)
1. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497 [TBL] [Abstract][Full Text] [Related]
2. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023 [TBL] [Abstract][Full Text] [Related]
3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
4. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903 [TBL] [Abstract][Full Text] [Related]
6. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358 [TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378 [TBL] [Abstract][Full Text] [Related]
8. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. Jacobsen H; Strengert M; Maaß H; Ynga Durand MA; Katzmarzyk M; Kessel B; Harries M; Rand U; Abassi L; Kim Y; Lüddecke T; Metzdorf K; Hernandez P; Ortmann J; Heise JK; Castell S; Gornyk D; Glöckner S; Melhorn V; Kemmling Y; Lange B; Dulovic A; Marsall P; Häring J; Junker D; Schneiderhan-Marra N; Hoffmann M; Pöhlmann S; Krause G; Cicin-Sain L Sci Rep; 2022 Nov; 12(1):19858. PubMed ID: 36400804 [TBL] [Abstract][Full Text] [Related]
9. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434 [TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection. Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY Front Immunol; 2023; 14():1131229. PubMed ID: 36960070 [TBL] [Abstract][Full Text] [Related]
11. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
12. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. GeurtsvanKessel CH; Geers D; Schmitz KS; Mykytyn AZ; Lamers MM; Bogers S; Scherbeijn S; Gommers L; Sablerolles RSG; Nieuwkoop NN; Rijsbergen LC; van Dijk LLA; de Wilde J; Alblas K; Breugem TI; Rijnders BJA; de Jager H; Weiskopf D; van der Kuy PHM; Sette A; Koopmans MPG; Grifoni A; Haagmans BL; de Vries RD Sci Immunol; 2022 Mar; 7(69):eabo2202. PubMed ID: 35113647 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520 [TBL] [Abstract][Full Text] [Related]
14. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338 [TBL] [Abstract][Full Text] [Related]
15. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
16. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Akkız H Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924 [TBL] [Abstract][Full Text] [Related]
17. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186 [TBL] [Abstract][Full Text] [Related]
19. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR Front Immunol; 2023; 14():1055429. PubMed ID: 36845123 [TBL] [Abstract][Full Text] [Related]
20. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection. Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]